JP5159307B2 - デシタビンポリモルフの組成物及び処方物並びにその使用方法 - Google Patents

デシタビンポリモルフの組成物及び処方物並びにその使用方法 Download PDF

Info

Publication number
JP5159307B2
JP5159307B2 JP2007521565A JP2007521565A JP5159307B2 JP 5159307 B2 JP5159307 B2 JP 5159307B2 JP 2007521565 A JP2007521565 A JP 2007521565A JP 2007521565 A JP2007521565 A JP 2007521565A JP 5159307 B2 JP5159307 B2 JP 5159307B2
Authority
JP
Japan
Prior art keywords
decitabine
cancer
polymorph
type
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007521565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008506690A (ja
JP2008506690A5 (https=
Inventor
サンジーヴ レドカー
ハンガル ラジャシュリー ジョシ
Original Assignee
アステックス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35600347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5159307(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アステックス ファーマシューティカルズ インコーポレイテッド filed Critical アステックス ファーマシューティカルズ インコーポレイテッド
Publication of JP2008506690A publication Critical patent/JP2008506690A/ja
Publication of JP2008506690A5 publication Critical patent/JP2008506690A5/ja
Application granted granted Critical
Publication of JP5159307B2 publication Critical patent/JP5159307B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2007521565A 2004-07-13 2005-07-12 デシタビンポリモルフの組成物及び処方物並びにその使用方法 Expired - Lifetime JP5159307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/890,828 2004-07-13
US10/890,828 US20060014949A1 (en) 2004-07-13 2004-07-13 Compositions and formulations of decitabine polymorphs and methods of use thereof
PCT/US2005/024676 WO2006017278A1 (en) 2004-07-13 2005-07-12 Compositions and formulations of decitabine polymorphs and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2008506690A JP2008506690A (ja) 2008-03-06
JP2008506690A5 JP2008506690A5 (https=) 2008-09-04
JP5159307B2 true JP5159307B2 (ja) 2013-03-06

Family

ID=35600347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007521565A Expired - Lifetime JP5159307B2 (ja) 2004-07-13 2005-07-12 デシタビンポリモルフの組成物及び処方物並びにその使用方法

Country Status (7)

Country Link
US (1) US20060014949A1 (https=)
EP (1) EP1765076A4 (https=)
JP (1) JP5159307B2 (https=)
CN (1) CN101014246A (https=)
AU (3) AU2005271814B2 (https=)
CA (1) CA2573332A1 (https=)
WO (1) WO2006017278A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
JP5687687B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
WO2010129211A2 (en) * 2009-04-27 2010-11-11 Dr. Reddy's Laboratories Ltd. Preparation of decitabine
CN101781347B (zh) * 2009-12-21 2012-09-12 南京卡文迪许生物工程技术有限公司 地西他滨多晶型物和药用组合物
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
EP2766041B1 (en) 2011-10-12 2018-12-05 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
US20140094598A1 (en) 2012-10-01 2014-04-03 Johnson Matthey Public Limited Company Method for the purification of decitabine
CN103191144B (zh) * 2013-04-25 2014-06-18 李伟丽 一种治疗癌症的药物组合物及应用
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
WO2019025256A1 (en) 2017-08-01 2019-02-07 Bayer Aktiengesellschaft COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
JP7089603B2 (ja) 2018-06-11 2022-06-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼疾患を治療するための脱メチル化
PH12022552250A1 (en) 2020-02-25 2023-11-13 Otsuka Pharma Co Ltd Combination decitabine and cedazuridine solid oral dosage forms
EP4138843A4 (en) 2020-04-23 2024-07-10 Southern Research Institute COMPOSITION FOR THE TREATMENT OF BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF
WO2022020747A1 (en) * 2020-07-23 2022-01-27 Southern Research Institute Polymorophs of 5-aza-4'-thio-2-deoxycytidine
CN119943194A (zh) * 2023-11-03 2025-05-06 中国石油天然气股份有限公司 一种分子筛晶胞参数确定方法和装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (https=) * 1963-12-22
CH527207A (de) * 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
JPS5213741B2 (https=) * 1972-05-22 1977-04-16
JPS5527077A (en) * 1978-08-16 1980-02-26 Shin Meiwa Ind Co Ltd Solids scraper for sludge dehydrator
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
KR101150250B1 (ko) * 2001-03-01 2012-06-12 아보트 래버러토리즈 시스-ｆｔｃ의 다형 및 기타 결정형
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract

Also Published As

Publication number Publication date
AU2011200540A8 (en) 2011-03-10
WO2006017278A1 (en) 2006-02-16
AU2011200540A1 (en) 2011-03-03
AU2011200539A1 (en) 2011-03-03
JP2008506690A (ja) 2008-03-06
EP1765076A1 (en) 2007-03-28
EP1765076A4 (en) 2009-04-22
US20060014949A1 (en) 2006-01-19
AU2005271814B2 (en) 2010-11-11
CN101014246A (zh) 2007-08-08
CA2573332A1 (en) 2006-02-16
AU2005271814A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
JP5159307B2 (ja) デシタビンポリモルフの組成物及び処方物並びにその使用方法
US7858594B2 (en) Crystalline and amorphous forms of beta-L-2′-deoxythymidine
US6696458B2 (en) Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
WO2006037024A2 (en) Salts of decitabine
CN110759908B (zh) 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
WO2006034154A2 (en) Salts of 5-azacytidine
WO2019001379A1 (zh) 用于抑制激酶活性的吲唑类化合物及其组合物及应用
JP2020529409A (ja) 薬物化合物およびその精製方法
TW201512192A (zh) 喹唑啉衍生物之固態形式及其作爲ｂｒａｆ抑制劑之用途
WO2019228330A1 (zh) 取代的苯并[d]咪唑类化合物及其药物组合物
CZ293433B6 (cs) Lyofilizované thioxantenonové protinádorové látky
HK1184163A (en) Amorphous form of beta- l-2'-deoxythymidine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121211

R150 Certificate of patent or registration of utility model

Ref document number: 5159307

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151221

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term